Today Pressure BioSciences Incorporated announced that it has added a new member to its senior executive management team; Vice President of Sales. Matthew B. Potter will now oversee Pressure Biosciences’ seven US-based, regional sales directors and will be responsible for driving the Company’s commercialization of their novel and patented pressure cycling technology (PCT) product line. Matthew Potter brings just short of twenty years of sales and management experience in both the pharmaceutical and biotechnology fields.
Potter has been a Sales Manager at Pharmacia Biotech; National Sales Director at Visible Genetics; Director, Sales and Marketing at MicroCal, LLC; National Sales Manager, Key Accounts — Pharma at Qiagen, Inc; and Vice President of Sales and Marketing at Abcam, Inc. Before his transition into sales, Mr. Potter was a researcher at the Worcester Foundation for Experimental Biology. Mr. Potter holds a BA in Biology from Clark University and an MBA from Assumption College, both located in Worcester, MA.
Potter said, “In over 19 years of selling products into the research marketplace for the analysis of nucleic acids, proteins, and small molecules, one issue — how to achieve high quality extraction of bio- molecules prior to analysis — nearly always rose to the top. This was always a key issue, and to that end, I believe strongly that the PCT Sample Preparation System answers many of the sample preparation problems that researchers encounter, and offers unique advantages to customers looking to extract DNA, RNA, proteins, and small molecules from a wide variety of biological samples. PBI has a dedicated and talented group of people throughout the organization, and I look forward to working with them — and in particular our newly hired field sales organization — to drive this technology into the marketplace.”
The addition of Potter was meant to give Dr. Nathan Lawrence, who previously led sales and marketing, an opportunity to focus solely on marketing both domestically and abroad. PBI’s Founder, President, and CEO, Richard T. Schumacher, said, “This new focus for Dr. Lawrence will allow us to align our sales and marketing efforts in a manner that supports our Company’s transition to a fully commercial operation in 2008.”
Let us hear your thoughts: Pressure BioSciences, Inc. Message Board